The axial spondyloarthritis (axSpA) treatment market comprises therapies and medications utilized in the treatment of axial spondyloarthritis disorders. Axial spondyloarthritis refers to chronic inflammatory diseases that primarily affect the sacroiliac joints and spine and cause back pain. The market has witnessed significant growth in the past few years due to the increasing prevalence of axial spondyloarthritis disorders globally. According to estimates, axial spondyloarthritis affects around 0.3 to 1.4 percent of the global population. The high physical impairment and reduced quality of life associated with axial spondyloarthritis have accelerated the demand for effective treatment options. Major drugs in the market include NSAIDs, biologics such as TNF inhibitors, and other newly introduced targeted therapies.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the axial spondyloarthritis (axSpA) treatment market are AbbVie Inc.,Novartis AG,Pfizer Inc.,UCB Pharma, and Eli Lilly and Company. AbbVie Inc. leads the TNF inhibitor segment with its blockbuster drug Humira. Novartis AG, with its recently launched drug Cosentyx, is making strong inroads into the TNF inhibitor market.
The Axial Spondyloarthritis (axSpA) Treatment Market offers promising growth opportunities such as the development and commercialization of JAK inhibitor drugs, novel targeted therapies, and pipeline drugs in late-stage clinical trials. Approval of potential blockbuster drugs can disrupt the existing treatment landscape.
Global players are expanding in high growth emerging markets through collaborations, licensing deals, and acquisitions. The growing diagnosis rate in Asia Pacific and Latin America presents lucrative expansion opportunities. New product introductions tailored for regional needs will drive further market penetration.
Market Drivers
Increasing diagnosis rates in developing countries resulting from enhanced awareness and screening programs. Early diagnosis aids effective disease management. Strong R&D pipeline with multiple late-stage candidates promising improved efficacy and safety over existing drugs. This will fuel product premiumization in the market.
Market Restrains
High drug development costs and regulatory hurdles for approval of novel entities. Only a few drugs make it from Phase III results to commercialization creating pressures. Patent expiries of blockbuster drugs enabling biosimilar competition and potential price erosion in the TNF inhibitor segment between 2023-2028. This challenges the market hegemony of incumbents.
Segment Analysis
The global axial spondyloarthritis (axSpA) treatment market is segmented into non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) segments. The nr-axSpA is dominating the market currently due to increasing diagnosis rate and growing awareness regarding the disease. This less severe form of the disease is often misdiagnosed as non-specific back pain in early stages. However, developing newer diagnostic tests are helping in early and accurate diagnosis of nr-axSpA.
Global Analysis
Regionally, North America holds the largest share in the global axSpA treatment market due to increasing awareness initiatives by various foundations and growth in biologic therapy options in the region. However, Asia Pacific is expected to witness the highest growth during the forecast period owing to improving healthcare infrastructure and rising healthcare expenditure in emerging countries like China and India. Increased availability of biosimilar drugs in Asia will also contribute to the strong market growth in this region. Additionally, growing patient population due to sedentary lifestyle and changing dietary patterns will support regional market expansion.
Get This Report in Japanese Language: 軸性脊椎関節炎（axSpA）治療市場
Get This Report in Korean Language: 축성 척추관절염(axSpA) 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
Non-radiographic axial spondyloarthritis market is a type of inflammatory arthritis, a hetrogenous group of autoimmune disorders that causes pain in lower back.
The non-radiographic means that the symptoms or inflammation will not visible on x-ray (radiograph) but can show on MRI (magnetic resonance imaging) scan however it can negative too and axial spondyloarthritis means arthritis affect mainly on the spine.
The patients with non- radiographic axial spondyloarthritis experience the severe back pain.According to the statistics puplished in the UCB S.A., an estimated adult population of non-radiographic axial spondyloarthritis is up to 0.5% to 1.4%.
Growing incidence of non-radiographic axial spondyloarthritis, accelerating demand of novel therapies and treatment are the key drivers for market growthThis Non-Radiographic Axial Spondyloarthritis Therapeutics Market research report intensely analyses the potential of the market with respect to current scenario and the future prospects by considering several industry aspects of Cardinal Health industry.
The report also recognizes and analyses the rising trends along with major drivers, challenges and opportunities in the market.
This Non-Radiographic Axial Spondyloarthritis Therapeutics Market report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in Healthcare industry.
